Ariana Pelosci

Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.

Suicide risk increased among patients who had a lower-income and lived in rural counties following a cancer diagnosis.

Enobosarm was granted fast track designation by the FDA for the treatment of patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Patients with stage IB to IIIA non–small cell lung cancer saw an improvement in disease-free survival when treated with pembrolizumab compared with the placebo regardless of PD-L1 expression.

Treatment with CA-4948 monotherapy yielded positive safety data and efficacy for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; CI-8993 also appeared to show promise in patients with relapsed/refractory solid tumors.

Patients with endometrial cancer who were treated with 30 Gy of 6 fractions of vaginal cuff brachytherapy presented with lower toxicity.

Telisotuzumab vedotin’s breakthrough therapy designation for EGFR wild-type non–small cell lung cancer was supported by results from the phase 2 LUMINOSITY trial.

Patients with relapsed or refractory multiple myeloma may benefit from treatment with teclistamab, for which a biologics license application was submitted to the FDA.

The combination of nivolumab plus ipilimumab demonstrated a survival benefit among patients with active melanoma and brain metastases.

A longer treatment-free survival was seen in patients with advanced renal cell carcinoma who were treated with first-line nivolumab and ipilimumab compared with sunitinib.

An interim analysis demonstrated positive efficacy and safety in patients with metastatic solid tumors who were treated with etigilimab plus nivolumab.

Black and Hispanic patients continue to be notably underrepresented in clinical cancer research, although research noted that participation is on the rise.

Early relapsed appears to be an important predictor of survival among patients with mantle cell lymphoma.

Although findings suggest that close or positive surgical margins are associated with a higher risk of poor outcomes in salivary gland cancer, it did not appear to be an independent factor for poor outcomes after adjusting for tumor stage, histologic risk group, and adjuvant radiotherapy use.

Philip S. Low, PhD, discusses the obstacles he overcame while creating pafolacianine and what other cancers he hopes will be improved with the use of this agent.

Patients with advanced rectal cancer who were treated with up-front chemoradiotherapy plus consolidation chemotherapy experienced an improvement in pathological complete response without impacting disease-free survival.

Paolo Tarantino, MD, hosted a Twitter Takeover during the San Antonio Breast Cancer Symposium where he discussed abstract presentations and key takeaways in a #CNRealTimeReport.

NUV-422 has demonstrated favorable blood-brain barrier penetration in patients with high-grade gliomas.

Elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit vs those who received rituximab and bendamustine.

A study presented at 2021 ASH found that costs and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia who were being treated with acalabrutinib, ibrutinib, and venetoclax.

Patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival than those who waited and received second-line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma.

The anti-TIGIT therapy tiragolumab administered in combination with atezolizumab showed clinically meaningful improvement at the 2.5-year follow-up vs atezolizumab alone for patients with PD-L1–positive metastatic non–small cell lung cancer.

A phase 3 trial analysis found that metformin does not improve invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status.

Patients with newly diagnosed glioblastoma who were treated with paxalisib saw positive efficacy and safety results.

A United States indication for duvelisib in previously treated relapsed/refractory follicular lymphoma has been voluntarily withdrawn by developer Secura Bio following an assessment of the drug and subsequent consultation with the FDA.

The use of alectinib to treat ALK-positive non–small cell lung cancer resulted in better overall survival compared with ceritinib.

Samilia Obeng-Gyasi discussed the connection between stress and allostatic load and chemotherapy completion in patients with breast cancer.

Patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with zanubrutinib, obinutuzumab, and venetoclax experienced increased rates of undetectable minimal residual disease in peripheral blood and bone marrow.

Arfolitixorin was granted a fast track designation by the FDA for advanced colorectal cancer based on its potential to address unmet medical needs.

DNA sequencing to detect minimal residual disease and eventual relapse was more accurate than flow cytometry for adult and pediatric patients with acute lymphoblastic leukemia who have been treated with tisagenlecleucel.